[go: up one dir, main page]

ATE416791T1 - Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält - Google Patents

Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält

Info

Publication number
ATE416791T1
ATE416791T1 AT01932810T AT01932810T ATE416791T1 AT E416791 T1 ATE416791 T1 AT E416791T1 AT 01932810 T AT01932810 T AT 01932810T AT 01932810 T AT01932810 T AT 01932810T AT E416791 T1 ATE416791 T1 AT E416791T1
Authority
AT
Austria
Prior art keywords
cyclodextrin
glycopeptide antibiotic
composition containing
disclosed
pharmaceutical compositions
Prior art date
Application number
AT01932810T
Other languages
English (en)
Inventor
J Judice
Jeng-Pyng Shaw
Yongqi Mu
Michael Conner
John L Pace
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Application granted granted Critical
Publication of ATE416791T1 publication Critical patent/ATE416791T1/de

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01932810T 2000-05-02 2001-05-01 Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält ATE416791T1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US20117800P 2000-05-02 2000-05-02
US21314600P 2000-06-22 2000-06-22
US21341700P 2000-06-22 2000-06-22
US21341000P 2000-06-22 2000-06-22
US21341500P 2000-06-22 2000-06-22
US21342800P 2000-06-22 2000-06-22
US22672700P 2000-08-18 2000-08-18

Publications (1)

Publication Number Publication Date
ATE416791T1 true ATE416791T1 (de) 2008-12-15

Family

ID=27569291

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01932810T ATE416791T1 (de) 2000-05-02 2001-05-01 Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält

Country Status (12)

Country Link
US (5) US6858584B2 (de)
EP (1) EP1278549B1 (de)
JP (2) JP4870314B2 (de)
CN (1) CN1223378C (de)
AT (1) ATE416791T1 (de)
AU (1) AU2001259306A1 (de)
BR (1) BR0110530A (de)
CA (2) CA2726789A1 (de)
DE (1) DE60136926D1 (de)
ES (1) ES2316445T3 (de)
SI (1) SI1278549T1 (de)
WO (1) WO2001082971A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0110530A (pt) * 2000-05-02 2003-04-08 Theravance Inc Composições farmacêuticas contendo um antibiótico glicopeptìdico e uma ciclodextrina
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
TWI312785B (en) * 2001-08-24 2009-08-01 Theravance Inc Process for preparing vancomycin derivatives
TWI275594B (en) 2001-08-24 2007-03-11 Theravance Inc Process for preparing vancomycin phosphonate derivatives
US7499410B2 (en) * 2001-12-26 2009-03-03 Cisco Technology, Inc. Fibre channel switch that enables end devices in different fabrics to communicate with one another while retaining their unique fibre channel domain—IDs
US7599360B2 (en) * 2001-12-26 2009-10-06 Cisco Technology, Inc. Methods and apparatus for encapsulating a frame for transmission in a storage area network
GB0206930D0 (en) * 2002-03-23 2002-05-08 Univ Durham Method and apparatus for the formation of hydrophobic surfaces
US7406034B1 (en) 2002-04-01 2008-07-29 Cisco Technology, Inc. Methods and apparatus for fibre channel frame delivery
US7616637B1 (en) 2002-04-01 2009-11-10 Cisco Technology, Inc. Label switching in fibre channel networks
US7206288B2 (en) * 2002-06-12 2007-04-17 Cisco Technology, Inc. Methods and apparatus for characterizing a route in fibre channel fabric
US7433326B2 (en) * 2002-11-27 2008-10-07 Cisco Technology, Inc. Methods and devices for exchanging peer parameters between network devices
WO2004110473A1 (en) * 2003-05-27 2004-12-23 Theravance, Inc. Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent
TWI342312B (en) * 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
AU2005282241B2 (en) * 2004-09-08 2011-03-03 Chelsea Therapeutics, Inc. Quinazoline derivatives as metabolically inert antifolate compounds.
US7593324B2 (en) * 2004-10-25 2009-09-22 Cisco Technology, Inc. Graceful port shutdown protocol for fibre channel interfaces
US7916628B2 (en) * 2004-11-01 2011-03-29 Cisco Technology, Inc. Trunking for fabric ports in fibre channel switches and attached devices
BRPI0516657A (pt) 2004-11-29 2008-09-16 Univ Nagoya Nat Univ Corp derivados de monÈmero antibiótico de glicopeptìdeo
US7649844B2 (en) * 2004-12-29 2010-01-19 Cisco Technology, Inc. In-order fibre channel packet delivery
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
DE102005056194A1 (de) * 2005-11-21 2007-07-12 Combinature Biopharm Ag Neue Lipopeptid Zusammensetzungen
US7795207B2 (en) 2005-11-21 2010-09-14 Harald Labischinski Lipopeptide compositions
SG170037A1 (en) * 2005-11-28 2011-04-29 Verrow Pharmaceuticals Inc Compositions useful for reducing nephrotoxicity and methods of use thereof
US7658913B2 (en) * 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
MX2010010999A (es) * 2008-04-07 2011-02-22 Chelsea Therapeutics Inc Formas de sal cristalinas de compuestos antifolatos y metodos de fabricacion de las mismas.
EP2324041A4 (de) 2008-08-13 2012-06-13 Targanta Therapeutics Corp Phosphonierte rifamycine und ihre anwendung zur vermeidung und behandlung von knochen- und gelenkinfektionen
PL2337575T3 (pl) 2008-08-30 2016-09-30 Sposoby leczenia z użyciem pojedynczych dawek orytawancyny
US9682061B2 (en) 2009-04-28 2017-06-20 The Medicines Company Methods of treating bacterial infections using oritavancin
EP2451788A1 (de) * 2009-07-08 2012-05-16 Chelsea Therapeutics, Inc. Stabile kristalline polymorphe des dikaliumsalzes aus (s) -2- {4- [2- (2, 4-diamin0-chinaz0lin-6-yl) -ethyl]-benzoylamino} -4-methylen -pentandisäure
EP2496237A2 (de) * 2009-11-06 2012-09-12 Chelsea Therapeutics, Inc. Enzymhemmende verbindungen
US20110237609A1 (en) * 2010-03-29 2011-09-29 Chelsea Therapeutics, Inc. Antifolate compositions
US8658652B2 (en) 2010-12-07 2014-02-25 Chelsea Therapeutics, Inc. Antifolate combinations
WO2014152332A1 (en) 2013-03-15 2014-09-25 Melinta Therapeutics, Inc. Methods of treating infections in overweight and obese patients using antibiotics
US20160206688A1 (en) 2013-08-26 2016-07-21 The Medicines Company Methods for treating bacteremia and osteomyelitis using oritavancin
US9697843B2 (en) 2014-04-30 2017-07-04 Qualcomm Incorporated High band excitation signal generation
JP2019512538A (ja) * 2016-02-18 2019-05-16 メリンタ セラピューティクス、 インコーポレイテッドＭｅｌｉｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． オリタバンシン製剤
WO2017179003A1 (en) 2016-04-15 2017-10-19 Lupin Limited Topical compositions for ophthalmic and otic use
CN107325159A (zh) * 2016-04-29 2017-11-07 中国科学院上海药物研究所 一类万古霉素衍生物、其制备方法、药物组合物和用途
MX2018013584A (es) * 2016-05-09 2019-04-01 Xellia Pharmaceuticals Aps Formulaciones de antibioticos glicopeptidicos estabilizados.
US11072668B2 (en) 2017-01-03 2021-07-27 The University Of North Carolina At Chapel Hill Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
CA3055474A1 (en) 2017-03-28 2018-10-04 The University Of North Carolina At Chapel Hill Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto
MX2020000265A (es) 2017-07-07 2020-07-22 Epicentrx Inc Composiciones para la administración parenteral de agentes terapéuticos.
CN107987131B (zh) * 2017-11-16 2021-03-09 上海来益生物药物研究开发中心有限责任公司 一组具有抗耐药性细菌活性的化合物、其制备方法和应用
CA3091458A1 (en) 2018-03-06 2019-09-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto
BR112020025003A2 (pt) 2018-06-13 2021-03-23 Dybly Ag preparação de derivados de triazepina condensados e uso dos mesmos como inibidores de bet
AU2019414421B2 (en) 2018-12-28 2023-08-31 The University Of North Carolina At Chapel Hill Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto
US12257248B2 (en) 2020-09-01 2025-03-25 University Of South Florida Bronchodilators for treating obstructive lung disease
US20220133844A1 (en) 2020-10-30 2022-05-05 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014965A1 (de) 2020-12-16 2022-06-22 EVER Valinject GmbH Wässrige lösung
EP4014969A1 (de) 2020-12-16 2022-06-22 EVER Valinject GmbH Wässrige lösung
WO2024079223A1 (en) 2022-10-12 2024-04-18 Xellia Pharmaceuticals Aps Liquid dalbavancin composition

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US77280A (en) * 1868-04-28 John l
US87494A (en) * 1869-03-02 William h
US229775A (en) * 1880-07-06 Eobeet h
US73371A (en) * 1868-01-14 Robert moxley
US207797A (en) * 1878-09-10 Improvement in check-rein hooks
US63916A (en) * 1867-04-16 Improvement in cotton peess
US4371673A (en) 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
EP0094157B1 (de) 1982-04-30 1987-07-29 Takeda Chemical Industries, Ltd. Pharmazeutische Zusammensetzung und ihre Verwendung
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4698327A (en) * 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4643987A (en) * 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
US4639433A (en) * 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
EP0335545B2 (de) 1988-03-29 1998-09-23 University Of Florida Pharmazeutische Zusammensetzungen für die parenterale Anwendung
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
CA2031803C (en) * 1989-12-13 2001-05-29 Ramakrishnan Nagarajan Improvements in or relating to glycopeptide deriveratives
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9012663D0 (en) * 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins
HUT63440A (en) 1990-06-15 1993-08-30 Ca Nat Research Council Proccess for producing thrombin inhibitors based on amino acid sequence of hirudine and pharmaceutical compositions comprising same
US5750509A (en) * 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
ES2104845T3 (es) * 1991-10-16 1997-10-16 Schering Corp Composiciones lipofilas de sales de antibioticos oligosacaridos.
IT1251751B (it) * 1991-10-31 1995-05-23 Sclavo Ricerca S R L Metodo per la coltura di microrganismi dei generi helicobacter, campylobacter e arcobacter, utilizzando terreni di coltura contenenti ciclodestrine o metil-cellulosa o loro miscele
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
JPH08503951A (ja) * 1992-12-02 1996-04-30 インサイト・ビジョン・インコーポレイテッド シクロデキストリンとポリマーを用いた薬剤供給系
WO1994020136A1 (en) 1993-03-08 1994-09-15 Department Of The Army, United States Government Cyclodextrin-peptide compositions
CA2156719A1 (en) 1993-03-12 1994-09-15 Ramesh Prakash Recombinant epstein-barr virus protein and its use in vaccine
WO1995011921A1 (en) 1993-10-25 1995-05-04 National Research Council Of Canada Bivalent thrombin inhibitors
US5840684A (en) * 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
PE40996A1 (es) 1994-01-28 1996-10-14 Lilly Co Eli Derivado de antibiotico de glucopeptido
SE510830C2 (sv) * 1995-02-16 1999-06-28 Pure Pulse Technologies Inc Sätt att med god hållbarhet förpacka färskt kött i en förpackning av plast
US5919756A (en) 1996-06-28 1999-07-06 Eli Lilly And Company Amides
CA2232435C (en) * 1996-08-09 2006-11-14 Alcon Laboratories, Inc. Preservative systems for pharmaceutical compositions containing cyclodextrins
US5776912A (en) * 1996-12-20 1998-07-07 Schering Corporation Lipophilic oligosaccharide antibiotic compositions
US5916873A (en) * 1997-04-17 1999-06-29 Eli Lilly And Company Teicoplanin derivatives
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
ATE323110T1 (de) * 1997-07-01 2006-04-15 Pfizer Prod Inc Verfahren zur herstellung von einem cyclodextrin
GB2344713B (en) * 1998-02-10 2003-05-07 Furuno Electric Co Display system
JP2003512017A (ja) 1998-12-23 2003-04-02 アベンティス、パストゥール、リミテッド クラミジア抗原および対応するｄｎａ断片ならびにその使用
CZ301184B6 (cs) * 1998-12-23 2009-12-02 Theravance, Inc. Glykopeptidový derivát a farmaceutické prostredky, které jej obsahují
DE19911097A1 (de) * 1999-03-12 2000-09-14 Basf Ag Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen
WO2000059528A1 (en) 1999-04-02 2000-10-12 The Trustees Of Princeton University Desleucyl glycopeptide antibiotics and methods of making same
BR0110530A (pt) 2000-05-02 2003-04-08 Theravance Inc Composições farmacêuticas contendo um antibiótico glicopeptìdico e uma ciclodextrina
US6770621B2 (en) 2000-05-02 2004-08-03 Theravance, Inc. Polyacid glycopeptide derivatives
ATE510533T1 (de) 2000-06-21 2011-06-15 Cubist Pharm Inc Arzneizusammensetzungen und verfahren zum verbessern der oralen absorption von antimikrobiellen wirkstoffen
WO2001098329A1 (en) 2000-06-22 2001-12-27 Theravance, Inc. Polyhydroxy glycopeptide derivatives
DE60133198T2 (de) 2000-06-22 2009-03-12 Theravance, Inc., South San Francisco Glykopeptidderivate mit carboxysacchariden
US6872804B2 (en) 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
AU2001259302A1 (en) * 2000-06-22 2002-01-02 Yongqi Mu Glycopeptide disulfide and thioester derivatives
US6969706B1 (en) * 2004-05-12 2005-11-29 Allergan, Inc. Preserved pharmaceutical compositions comprising cyclodextrins
WO2010004060A1 (es) * 2008-07-11 2010-01-14 Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Marañon Uso de la cilastatina para reducir la nefrotoxicidad de distintos compuestos

Also Published As

Publication number Publication date
US8158580B2 (en) 2012-04-17
CN1223378C (zh) 2005-10-19
CA2408008C (en) 2011-01-18
JP2003531869A (ja) 2003-10-28
US7544364B2 (en) 2009-06-09
US20020077280A1 (en) 2002-06-20
CN1441680A (zh) 2003-09-10
AU2001259306A1 (en) 2001-11-12
US7067483B2 (en) 2006-06-27
US20050032676A1 (en) 2005-02-10
US20060194717A1 (en) 2006-08-31
DE60136926D1 (de) 2009-01-22
EP1278549B1 (de) 2008-12-10
WO2001082971A2 (en) 2001-11-08
BR0110530A (pt) 2003-04-08
JP4870314B2 (ja) 2012-02-08
EP1278549A2 (de) 2003-01-29
US7026288B2 (en) 2006-04-11
US20050026820A1 (en) 2005-02-03
US6858584B2 (en) 2005-02-22
US20100081609A1 (en) 2010-04-01
JP2008231109A (ja) 2008-10-02
SI1278549T1 (sl) 2009-04-30
WO2001082971A3 (en) 2002-05-23
CA2408008A1 (en) 2001-11-08
CA2726789A1 (en) 2001-11-08
ES2316445T3 (es) 2009-04-16

Similar Documents

Publication Publication Date Title
DE60136926D1 (de) Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
PL361341A1 (pl) Nowa kompozycja farmaceutyczna
YU46097A (sh) Nova klasa estara i njihove farmaceutske smeše
BR9710768A (pt) Composto composi-Æo e processos para tratamento de infec-{es bacterianas em um mamifero hospedeiro com necessidade de tal tratamento e para prepara-Æo de 6-0-metileritromicina forma i
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
PT759774E (pt) Metodo para o tratamento de infeccoes bacterianas gram-negativas por administracao de um produto de proteina bactericida indutora da permeabilidade (bip) e de um antibiotico
BR9714287A (pt) Antibiótico cristalino designado solvato 6-o-metileritromicina forma 0, solvato de 6-o-metileritromicina forma 0, composição, processos para tratamento de infecções bacterianas em um mamìfero hospedeiro com necessidade de tal tratamento e para preparação de solvato de 6-o-metileritomicina a forma 0, 6-o-metileritromicina forma 0--etanolato, suspensão para administração oral, e, complexo de solvato de 6-o-metileritromicina a forma 0-carbÈmero.
TNSN06420A1 (en) Methods of treatment of endobronchial infections
DK1347730T4 (da) Rekombinante anti-CD30-antistoffer og anvendelser deraf
BR0000003A (pt) Azalidas e métodos de preparação das mesmas
AR034343A1 (es) Combinaciones farmaceuticas
ATE322265T1 (de) Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
BG105600A (en) 13-membered azalides and their use as antibiotic agents
DE60041753D1 (de) Arzneimittel zur behandlung von c. pneumoniae infektionen
EE200000587A (et) Uued 15-lülilised ketoasaliidid, meetod nende valmistamiseks ning neid sisaldav farmatseutiline kompositsioon kasutamiseks bakternakkuste ravis
HUP0004282A2 (hu) 2-Halogén-6-0-szubsztituált ketolidszármazékok
MXPA03011521A (es) Aminadioles para tratamiento de enfermedad de alzheimer.
EP0932613A4 (de) Expressionsblockierung von virulenten faktoren in s. aureus
DE60208404D1 (de) Kreuzverquerte glycopeptid-cephalosporin-antibiotika
BR0002577A (pt) Suspensões orais de trovafloxacina
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
MXPA03011502A (es) Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer.
BR0108096A (pt) Método para manter ou melhorar a sìntese de mucinas
DE60003074D1 (de) Fusidinsäure-derivate
AR030660A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties